Clinical Trial

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-01 -> 2031-07-01 2026-08-14
minor Completion pushed: 2027-07-01 -> 2032-07-01 2026-08-14
Trial Details
NCT Number NCT06040970
Lead Sponsor Icahn School of Medicine at Mount Sinai
Conditions Ovarian Cancer, Malignant Neoplasm of Uterus
Enrollment 54 participants
Start Date 2024-10-28
Primary Completion 2031-07-01 (estimated)
Study Completion 2032-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13